Screening for colorectal cancer: What is the impact on the determinants of outcome?

Critical Reviews in Oncology/Hematology

Volumn 85, Issue 3, 2013, Pages 342-349

  Mansouri, David ^a   McMillan, Donald C ^a   Crighton, Emilia M ^b   Horgan, Paul G ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b NHS GREATER GLASGOW AND CLYDE   (United Kingdom)

Author keywords

Colorectal cancer; Host related factors; Screening; Tumour related factors

Indexed keywords

ANTINEOPLASTIC AGENT;

CANCER GROWTH; CANCER MORTALITY; CANCER PROGNOSIS; CANCER SCREENING; CANCER STAGING; CARCINOGENESIS; CLINICAL FEATURE; COLONOSCOPY; COLORECTAL CANCER; COLORECTAL SURGERY; DEMOGRAPHY; EVIDENCE BASED MEDICINE; HIGH RISK POPULATION; HUMAN; LONG TERM SURVIVAL; MEDICAL DECISION MAKING; OCCULT BLOOD TEST; OUTCOME ASSESSMENT; OVERALL SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SIGMOIDOSCOPY; SURVIVAL RATE; UNITED KINGDOM;

COLORECTAL NEOPLASMS; EARLY DETECTION OF CANCER; GREAT BRITAIN; HUMANS; PROGNOSIS;

EID: 84873527071     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2012.08.006     Document Type: Review

References (60)

1. Cancer Research UK. (Accessed July 2012). http://info.cancerresearchuk.org/cancerstats/.
2. McArdle C.S., Hole D.J. Outcome following surgery for colorectal cancer: analysis by hospital after adjustment for case-mix and deprivation. British Journal of Cancer 2002, 86(3):331-335.
3. Wilson J.M., Jungner Y.G. Principles and practice of mass screening for disease. Boletin de la Oficina Sanitaria Panamericana 1968, 65(4):281-393.
4. Bretthauer M. Colorectal cancer screening. Journal of Internal Medicine 2011, 270(2):87-98.
5. Stryker S.J., Wolff B.G., Culp C.E., Libbe S.D., Ilstrup D.M., MacCarty R.L. Natural history of untreated colonic polyps. Gastroenterology 1987, 93(5):1009-1013.
6. Cairns S.R., Scholefield J.H., Steele R.J., Dunlop M.G., Thomas H.J.W., Evans G.D., et al. Guidelines for colorectal cancer screening and surveillance in moderate and high risk groups (update from 2002). Gut 2010, 59(5):666-689.
7. Hol L., van Leerdam M.E., van Ballegooijen M., van Vuuren A.J., van Dekken H., Reijerink J.C., et al. Screening for colorectal cancer: randomised trial comparing guaiac-based and immunochemical faecal occult blood testing and flexible sigmoidoscopy. Gut 2010, 59(1):62-68.
8. Levin B., Lieberman D.A., McFarland B., Andrews K.S., Brooks D., Bond J., et al. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. Gastroenterology 2008, 134(5):1570-1595.
9. Atkin W.S., Edwards R., Kralj-Hans I., Wooldrage K., Hart A.R., Northover J.M., et al. Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial. Lancet 2010, 375(9726):1624-1633.
10. Hol L., Wilschut J.A., van Ballegooijen M., van Vuuren A.J., van der Valk H., Reijerink J.C., et al. Screening for colorectal cancer: random comparison of guaiac and immunochemical faecal occult blood testing at different cut-off levels. British Journal of Cancer 2009, 100(7):1103-1110.
11. Caligiore P., Macrae F.A., St John D.J., Rayner L.J., Legge J.W. Peroxidase levels in food: relevance to colorectal cancer screening. The American Journal of Clinical Nutrition 1982, 35(6):1487-1489.
12. Hardcastle J.D., Chamberlain J.O., Robinson M.H., Moss S.M., Amar S.S., Balfour T.W., et al. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet 1996, 348(9040):1472-1477.
13. Kronborg O., Fenger C., Olsen J., Jorgensen O.D., Sondergaard O. Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet 1996, 348(9040):1467-1471.
14. Mandel J.S., Bond J.H., Church T.R., Snover D.C., Bradley G.M., Schuman L.M., et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. New England Journal of Medicine 1993, 328(19):1365-1371.
15. Towler B.P., Irwig L., Glasziou P., Weller D., Kewenter J. Screening for colorectal cancer using the faecal occult blood test, hemoccult. Cochrane Database of Systematic Reviews 2000, 2. CD001216.
16. Group UCCSP Results of the first round of a demonstration pilot of screening for colorectal cancer in the United Kingdom. British Medical Journal 2004, 329(7458):133.
17. Hewitson P., Glasziou P., Irwig L., Towler B., Watson E. Screening for colorectal cancer using the faecal occult blood test, hemoccult. Cochrane Database of Systematic Reviews 2007, 1. CD001216.
18. Lindholm E., Brevinge H., Haglind E. Survival benefit in a randomized clinical trial of faecal occult blood screening for colorectal cancer. British Journal of Surgery 2008, 95(8):1029-1036.
19. Larsen I.K., Grotmol T., Almendingen K., Hoff G. Impact of colorectal cancer screening on future lifestyle choices: a three-year randomized controlled trial. Clinical Gastroenterology and Hepatology 2007, 5(4):477-483.
20. Hoff G., Thiis-Evensen E., Grotmol T., Sauar J., Vatn M.H., Moen I.E. Do undesirable effects of screening affect all-cause mortality in flexible sigmoidoscopy programmes? Experience from the Telemark Polyp Study 1983-1996. European Journal of Cancer Prevention 2001, 10(2):131-137.
21. Mandel J.S., Church T.R., Bond J.H., Ederer F., Geisser M.S., Mongin S.J., et al. The effect of fecal occult-blood screening on the incidence of colorectal cancer. New England Journal of Medicine 2000, 343(22):1603-1607.
22. Scholefield J.H., Moss S.M., Mangham C.M., Whynes D.K., Hardcastle J.D. Nottingham trial of faecal occult blood testing for colorectal cancer: a 20-year follow-up. Gut 2011, 61(7):1036-1040.
23. McClements P.L., Madurasinghe V., Thomson C.S., Fraser C.G., Carey F.A., Steele R.J., et al. Impact of the UK colorectal cancer screening pilot studies on incidence, stage distribution and mortality trends. Cancer Epidemiology 2012, 36(4):e232-e242.
24. Dukes C.E., Bussey H.J. The spread of rectal cancer and its effect on prognosis. British Journal of Cancer 1958, 12(3):309-320.
25. Steele R.J., McClements P.L., Libby G., Black R., Morton C., Birrell J., et al. Results from the first three rounds of the Scottish demonstration pilot of FOBT screening for colorectal cancer. Gut 2009, 58(4):530-535.
26. McArdle C.S., Hole D.J. Emergency presentation of colorectal cancer is associated with poor 5-year survival. British Journal of Surgery 2004, 91(5):605-609.
27. McArdle C.S., McMillan D.C., Hole D.J. The impact of blood loss, obstruction and perforation on survival in patients undergoing curative resection for colon cancer. British Journal of Surgery 2006, 93(4):483-488.
28. Scholefield J.H., Robinson M.H., Mangham C.M., Hardcastle J.D. Screening for colorectal cancer reduces emergency admissions. European Journal of Surgical Oncology 1998, 24(1):47-50.
29. Logan R.F., Patnick J., Nickerson C., Coleman L., Rutter M.D., von Wagner C. Outcomes of the Bowel Cancer Screening Programme (BCSP) in England after the first 1 million tests. Gut 2011, [Epub ahead of print].
30. Harmston C., Hunter J., Wong L. Does the location of screen-detected cancers differ from that seen in the unscreened population?. Colorectal Disease 2010, 12(4):324-326.
31. Steele R.J., McClements P., Watling C., Libby G., Weller D., Brewster D.H., et al. Interval cancers in a FOBT-based colorectal cancer population screening programme: implications for stage, gender and tumour site. Gut 2012, 61(4):576-581.
32. Rea J.D., Lu K.C., Diggs B.S., Cone M.M., Hardiman K.M., Herzig D.O. Specialized practice reduces inpatient mortality, length of stay, and cost in the care of colorectal patients. Diseases of the Colon and Rectum 2011, 54(7):780-786.
33. Garcia-Granero E., Marti-Obiol R., Gomez-Barbadillo J., Garcia-Armengol J., Esclapez P., Espi A., et al. Impact of surgeon organization and specialization in rectal cancer outcome. Colorectal Disease 2001, 3(3):179-184.
34. Platell C., Barwood N., Dorfmann G., Makin G. The incidence of anastomotic leaks in patients undergoing colorectal surgery. Colorectal Disease 2007, 9(1):71-79.
35. Mirnezami A., Mirnezami R., Chandrakumaran K., Sasapu K., Sagar P., Finan P. Increased local recurrence and reduced survival from colorectal cancer following anastomotic leak: systematic review and meta-analysis. Annals of Surgery 2011, 253(5):890-899.
36. Dube S., Heyen F., Jenicek M. Adjuvant chemotherapy in colorectal carcinoma: results of a meta-analysis. Diseases of the Colon and Rectum 1997, 40(1):35-41.
37. Horgan P.G., McMillan D.C. Surgeons and selection of adjuvant therapy for node-negative colonic cancer. British Journal of Surgery 2010, 97(10):1459-1460.
38. Compton C., Fenoglio-Preiser C.M., Pettigrew N., Fielding L.P. American Joint Committee on Cancer Prognostic Factors Consensus Conference: Colorectal Working Group. Cancer 2000, 88(7):1739-1757.
39. Compton C.C., Fielding L.P., Burgart L.J., Conley B., Cooper H.S., Hamilton S.R., et al. Prognostic factors in colorectal cancer. College of American Pathologists Consensus Statement 1999. Archives of Pathology and Laboratory Medicine 2000, 124(7):979-994.
40. Derwinger K., Kodeda K., Bexe-Lindskog E., Taflin H. Tumour differentiation grade is associated with TNM staging and the risk of node metastasis in colorectal cancer. Acta Oncologica 2010, 49(1):57-62.
41. Petersen V.C., Baxter K.J., Love S.B., Shepherd N.A. Identification of objective pathological prognostic determinants and models of prognosis in Dukes' B colon cancer. Gut 2002, 51(1):65-69.
42. Pollheimer M.J., Kornprat P., Lindtner R.A., Harbaum L., Schlemmer A., Rehak P., et al. Tumor necrosis is a new promising prognostic factor in colorectal cancer. Human Pathology 2010, 41(12):1749-1757.
43. Richards C.H., Roxburgh C.S., Anderson J.H., McKee R.F., Foulis A.K., Horgan P.G., et al. Prognostic value of tumour necrosis and host inflammatory responses in colorectal cancer. British Journal of Surgery 2012, 99(2):287-294.
44. Kay B.R., Witte D.L. The impact of cancer biology, lead time bias, and length bias in the debate about cancer screening tests. Journal of Insurance Medicine 1991, 23(2):102-104.
45. Whynes D.K., Frew E.J., Manghan C.M., Scholefield J.H., Hardcastle J.D. Colorectal cancer, screening and survival: the influence of socio-economic deprivation. Public Health 2003, 117(6):389-395.
46. Oliphant R., Brewster D.H., Morrison D.S. The changing association between socioeconomic circumstances and the incidence of colorectal cancer: a population-based study. British Journal of Cancer 2011, 104(11):1791-1796.
47. Hole D.J., McArdle C.S. Impact of socioeconomic deprivation on outcome after surgery for colorectal cancer. British Journal of Surgery 2002, 89(5):586-590.
48. Knight K., Wade S., Balducci L. Prevalence and outcomes of anemia in cancer: a systematic review of the literature. American Journal of Medicine 2004, 116(Suppl 7A):11S-26S.
49. Tampellini M., Saini A., Alabiso I., Bitossi R., Brizzi M.P., Sculli C.M., et al. The role of haemoglobin level in predicting the response to first-line chemotherapy in advanced colorectal cancer patients. British Journal of Cancer 2006, 95(1):13-20.
50. Colotta F., Allavena P., Sica A., Garlanda C., Mantovani A. Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis 2009, 30(7):1073-1081.
51. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100(1):57-70.
52. Proctor M.J., Morrison D.S., Talwar D., Balmer S.M., O'Reilly D.S., Foulis A.K., et al. An inflammation-based prognostic score (mGPS) predicts cancer survival independent of tumour site: a Glasgow Inflammation Outcome Study. British Journal of Cancer 2011, 104(4):726-734.
53. McMillan D.C., Crozier J.E., Canna K., Angerson W.J., McArdle C.S. Evaluation of an inflammation-based prognostic score (GPS) in patients undergoing resection for colon and rectal cancer. International Journal of Colorectal Disease 2007, 22(8):881-886.
54. Crozier J.E., McKee R.F., McArdle C.S., Angerson W.J., Anderson J.H., Horgan P.G., et al. Preoperative but not postoperative systemic inflammatory response correlates with survival in colorectal cancer. British Journal of Surgery 2007, 94(8):1028-1032.
55. Crozier J.E., McKee R.F., McArdle C.S., Angerson W.J., Anderson J.H., Horgan P.G., et al. The presence of a systemic inflammatory response predicts poorer survival in patients receiving adjuvant 5-FU chemotherapy following potentially curative resection for colorectal cancer. British Journal of Cancer 2006, 94(12):1833-1836.
56. Ishizuka M., Nagata H., Takagi K., Horie T., Kubota K. Inflammation-based prognostic score is a novel predictor of postoperative outcome in patients with colorectal cancer. Annals of Surgery 2007, 246(6):1047-1051.
57. Ishizuka M., Nagata H., Takagi K., Kubota K. Influence of inflammation-based prognostic score on mortality of patients undergoing chemotherapy for far advanced or recurrent unresectable colorectal cancer. Annals of Surgery 2009, 250(2):268-272.
58. Roxburgh C.S., Crozier J.E., Maxwell F., Foulis A.K., Brown J., McKee R.F., et al. Comparison of tumour-based (Petersen Index) and inflammation-based (Glasgow Prognostic Score) scoring systems in patients undergoing curative resection for colon cancer. British Journal of Cancer 2009, 100(5):701-706.
59. Roxburgh C.S., McMillan D.C. The role of the in situ local inflammatory response in predicting recurrence and survival in patients with primary operable colorectal cancer. Cancer Treatment Reviews 2012, 38(5):451-466.
60. Klintrup K., Makinen J.M., Kauppila S., Vare P.O., Melkko J., Tuominen H., et al. Inflammation and prognosis in colorectal cancer. European Journal of Cancer 2005, 41(17):2645-2654.